RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - Redhill Biopharma (NASDAQ:RDHL)

TEL AVIV, Israel & RALEIGH, N.C., Sept. 22, 2023 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on

Related Keywords

United Kingdom ,Redhill Biopharma ,Adi Frish ,Redhill Adss ,Corporate Business Development ,Company American Depositary Shares Adss ,Exchange Commission ,Nasdaq ,Nasdaq Stock Market ,Redhill Biopharma Ltd ,Product Development Pipeline ,Company Adss ,Nasdaq Hearings Panel The ,Listings Qualifications Department ,Company Annual Report On Form ,Company Expanded Access Program ,American Depositary Shares ,Nasdaq Global Market ,Nasdaq Listing Rule ,Nasdaq Listing Rules ,Nasdaq Hearings Panel ,Acute Radiation Syndrome ,Private Securities Litigation Reform Act ,Development Pipeline ,Expanded Access Program ,Annual Report ,Hill Biopharma ,